ATE348608T1 - Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne - Google Patents

Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne

Info

Publication number
ATE348608T1
ATE348608T1 AT04075431T AT04075431T ATE348608T1 AT E348608 T1 ATE348608 T1 AT E348608T1 AT 04075431 T AT04075431 T AT 04075431T AT 04075431 T AT04075431 T AT 04075431T AT E348608 T1 ATE348608 T1 AT E348608T1
Authority
AT
Austria
Prior art keywords
migraines
hiv
colon cancer
receptor ligand
use against
Prior art date
Application number
AT04075431T
Other languages
English (en)
Inventor
Mark Bamford
Richard Howard Green
Richard Coles
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918745.2A external-priority patent/GB9918745D0/en
Priority claimed from GBGB9928437.4A external-priority patent/GB9928437D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE348608T1 publication Critical patent/ATE348608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04075431T 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne ATE348608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918745.2A GB9918745D0 (en) 1999-08-10 1999-08-10 Medical uses
GBGB9928437.4A GB9928437D0 (en) 1999-12-01 1999-12-01 Medical uses

Publications (1)

Publication Number Publication Date
ATE348608T1 true ATE348608T1 (de) 2007-01-15

Family

ID=26315833

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
AT04075431T ATE348608T1 (de) 1999-08-10 2000-08-08 Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00956408T ATE272398T1 (de) 1999-08-10 2000-08-08 Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz

Country Status (8)

Country Link
US (1) US6861441B1 (de)
EP (2) EP1202730B1 (de)
JP (1) JP2003506404A (de)
AT (2) ATE272398T1 (de)
AU (1) AU6836200A (de)
DE (2) DE60012751T2 (de)
ES (2) ES2274378T3 (de)
WO (1) WO2001010426A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
CA2402099C (en) * 2000-03-24 2011-04-26 Pharmagene Laboratories Ltd. Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
ES2292814T3 (es) * 2001-10-31 2008-03-16 Medical Research Council Antagonistas de los receptores ep2 y/o ep4 de la prostaglandina para el tratamiento de la menorragia.
EP1563846B1 (de) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogene reparaturfaktoren herstellende promoter
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20090036495A1 (en) * 2004-04-20 2009-02-05 Pfizer, Inc. Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
GB0602900D0 (en) * 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
GB0615111D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0616498D0 (en) * 2006-08-18 2006-09-27 Glaxo Group Ltd Novel compounds
GB0620619D0 (en) * 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) * 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
WO2008136519A1 (ja) * 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
GB0715463D0 (en) * 2007-08-08 2007-09-19 Glaxo Group Ltd Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
JP2015522528A (ja) 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 慢性閉塞性肺疾患の予防または治療方法および医薬組成物
EP2913047B1 (de) 2012-10-29 2019-05-08 Cardio Incorporated Spezifisches therapeutikum für pulmonale erkrankungen
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
CA2941008C (en) * 2014-03-06 2022-07-26 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574409A5 (en) * 1972-09-29 1976-04-15 Sandoz Ag Benzo(f)isoindoline derivs - with antidepressant and analgesic activity
IL62734A (en) 1980-04-30 1985-10-31 Glaxo Group Ltd Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
NO872963L (no) * 1986-07-29 1988-02-01 Glaxo Group Ltd Isokinolinderivater.
EP0501579A1 (de) 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
EP0520573A1 (de) 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
CA2189053A1 (en) 1994-04-29 1995-11-09 Shigenori Ohkawa Condensed heterocyclic compounds, their production and use as gnrh antagonists
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors

Also Published As

Publication number Publication date
DE60032524D1 (de) 2007-02-01
DE60012751D1 (de) 2004-09-09
ES2274378T3 (es) 2007-05-16
EP1442744A3 (de) 2005-04-06
EP1442744A2 (de) 2004-08-04
JP2003506404A (ja) 2003-02-18
US6861441B1 (en) 2005-03-01
WO2001010426A3 (en) 2001-12-20
EP1202730A2 (de) 2002-05-08
DE60032524T2 (de) 2007-07-05
EP1202730B1 (de) 2004-08-04
DE60012751T2 (de) 2005-01-20
AU6836200A (en) 2001-03-05
ATE272398T1 (de) 2004-08-15
WO2001010426A2 (en) 2001-02-15
ES2225199T3 (es) 2005-03-16
EP1442744B1 (de) 2006-12-20

Similar Documents

Publication Publication Date Title
ATE348608T1 (de) Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne
ATE350036T1 (de) Tetrahydroquinolin-derivate
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
EP2269657A3 (de) Prodrugs mit neuen biospaltbaren Verbindern
WO2001058869A3 (en) Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
ATE278661T1 (de) Anthranilsäurederivate
ATE498600T1 (de) Inden derivate als pharmazeutika
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE69810960T2 (de) 2-phenoxyanilin-derivate
DE69717453D1 (de) Amid derivate
DE60330391D1 (de) Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
DE60013994D1 (de) 1,2-Disubstituierte 1,4-Dihydro-4-oxochinolin-Verbindungen
ATE451382T1 (de) 4-substituierte-3,6-anhydro-galaktosederivate und ihre pharmazeutische verwendung
DE69814563D1 (de) Pyrrolo-(3,2-b)pyridine und ihre Verwendung als 5-HT1F Agonisten
DE60020246D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE319452T1 (de) Arzneimittel gegen essstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties